Serial Number
98211995
Owner
Neurocrine Biosciences, Inc.Attorney
Allison Strickland RickettsFiling Date
Oct 6, 2023
ERUDITE Trademark
Serial Number: 98211995
Trademark Classes
Owner Contact Info
6027 Edgewood Bend Court
San Diego, CA 92130
Entity Type: 03
Legal Representation
Correspondence Address
ALLISON STRICKLAND RICKETTS FROSS ZELNICK LEHRMAN & ZISSU, P.C.
151 WEST 42ND ST., 17TH FL.
NEW YORK, NY 10036
UNITED STATES
Trademark Details
Filing Date
October 6, 2023
Registration Date
Not Registered
Published for Opposition
June 25, 2024
Goods & Services
Providing medical information; providing medical information relating to therapies and treatments for cognitive impairment associated with schizophrenia and mental illness and disorders
Pharmaceutical research and development services; conducting clinical trials for others for pharmaceutical preparations; pharmaceutical research services and pharmaceutical product evaluation, namely, conducting post-authorization research for the marketing of pharmaceutical preparations and evaluating epidemiological results; pharmaceutical research and development services in the field of cognitive impairment associated with schizophrenia and mental illness and disorders; conducting clinical trials for others for pharmaceutical preparations for the treatment and prevention of cognitive impairment associated with schizophrenia and mental illness and disorders; pharmaceutical research services and pharmaceutical product evaluation, namely, conducting post-authorization research for the marketing of pharmaceutical preparations for the treatment and prevention of cognitive impairment associated with schizophrenia and mental illness and disorders, and evaluating epidemiological results for treatments for cognitive impairment associated with schizophrenia and mental illness and disorders; providing medical and scientific research information to patients and practitioners in the field of clinical trials, namely, as to the results of clinical trials; providing medical and scientific research information to patients and practitioners in the field of clinical trials, namely, as to the results of clinical trials pertaining to therapies and treatments for cognitive impairment associated with schizophrenia and mental illness and disorders